Advantageous properties of gestodene and its use in combined hormonal contraception

Czech version

Authors: Tomáš Fait
Authors‘ workplace: Gynekologicko-porodnická klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Alois Martan, DrSc.
Published in: Prakt Gyn 2014; 18(2): 110-113
Category: Gynecology and Obstetrics: Review Article

Overview

Gestodene is a derivative of 19-nortestosterone and gonan with no residual androgenic activity. It belongs to the 3rd generation of progestins. Monophasic combination of 20 µg EE and 75 µg GSD has been clinically proven contraceptive with high efficiency and high compliance of patients. In trials it has been shown its metabolic neutrality, minimal risk in body weight changes, no blood pressure changes, sufficient anti-androgenic effect and good control of pseudomenstruation cycle.

Key words:
combined oral contraceptives – gestodene

Sources

1. Fait T. Antikoncepce. 2. vydání. Maxdorf: Praha 2012. ISBN 978–80–7345–280–3.

2. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996; 51(2): 188–215.

3. Jung-Hoffmann C, Kuhl H. Interaction with the pharmacokinetics of ethinyelstradiol and progestogens contained in oral contraceptives. Contraception 1989; 40(3): 299–312.

4. Pierard-Franchimont G, Gaspard U, Lacante P et al. A quantitative biometrological assessment of acne and hormonal evaluation in young women using a triphasic low-dose oral contraceptive containing gestodene. Eur J Contracept Reprod Health Care 2000; 5(4): 275–286.

5. Nikolov A. Influence of the very low dose oral contraception on the blood presure, body weight, and general condition of the patients. Akush Ginekol (Sofia) 2009; 48(4): 11–16.

6. Endrikat J, Müller U, Düsterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 1997; 55(3): 131–137.

7. Lech MM, Swiatek EJ. The effectiveness and acceptability of oral contraceptives (Logest), containing 20 micrograms ethinylestradiol and 75 micrograms gestodene. Ginekol Pol 2004, 75(3): 209–214.

8. Dusterberg B, Ellman H, Müller U et at. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene. Gynecol Endocrinol 1996; 10(1): 33–39.

9. Endrikat J, Jaques MA, Mayerhofer M et al. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance. Contraception 1995; 52(4): 229–235.

10. Endrikat J, Dusterberg B, Ruebig A et al. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception 1999; 60(5): 269–274.